Literature DB >> 28380465

Impact of interaction between the G870A and EFEMP1 gene polymorphism on glioma risk in Chinese Han population.

Libin Yang1, Bo Qu1, Xun Xia1, Yongqin Kuang1, Jian Li2, Kexia Fan1, Heng Guo1, Hui Zheng1, Yuan Ma1.   

Abstract

AIMS: To investigate the impact of CCND1 and EFEMP1 gene polymorphism, and additional their gene-gene interactions and haplotype within EFEMP1 gene on glioma risk based on Chinese population.
METHODS: Logistic regression was performed to investigate association between single-nucleotide polymorphisms (SNP) and glioma risk and generalized multifactor dimensionality reduction (GMDR) was used to analyze the gene-gene interaction.
RESULTS: Glioma risks were higher in carriers of homozygous mutant of rs603965 within CCND1 gene, rs1346787 and rs3791679 in EFEMP1 gene than those with wild-type homozygotes, OR (95%CI) were 1.67 (1.23-2.02), 1.59 (1.25-2.01) and 1.42 (1.15-1.82), respectively. GMDR analysis indicated a significant two-locus model (p=0.0010) involving rs603965 within CCND1 gene and rs1346787 within EFEMP1 gene. Overall, the cross-validation consistency of the two- locus models was 10\ 10, and the testing accuracy is 60.17%. Participants with rs603965 - GA or AA and rs1346787- AG or GG genotype have the highest glioma risk, compared to participants with rs603965 - GG and rs1346787- AA genotype, OR (95%CI) was 3.65 (1.81-5.22). We conducted haplotype analysis for rs1346787 and rs3791679, because D' value between rs1346787 and rs3791679 was more than 0.8. The most common haplotype was rs1346787 - A and rs3791679- G haplotype, the frequency of which was 0.4905 and 0.4428 in case and control group.
CONCLUSIONS: Polymorphism in rs603965 within CCND1 gene and rs1346787 within EFEMP1 gene and its gene- gene interaction were associated with increased glioma risk.

Entities:  

Keywords:  CCND1; EFEMP1; SNP; glioma; interaction

Mesh:

Substances:

Year:  2017        PMID: 28380465      PMCID: PMC5514930          DOI: 10.18632/oncotarget.16581

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  21 in total

1.  Cyclin D1 gene G870A variants and primary brain tumors.

Authors:  Umit Zeybek; Ilhan Yaylim; Nazli Ezgi Ozkan; Gurbet Korkmaz; Saime Turan; Didem Kafadar; Canan Cacina; Ali Metin Kafadar
Journal:  Asian Pac J Cancer Prev       Date:  2013

Review 2.  Fibulins and cancer: friend or foe?

Authors:  William M Gallagher; Caroline A Currid; Linda C Whelan
Journal:  Trends Mol Med       Date:  2005-07       Impact factor: 11.951

3.  Association of EFEMP1 gene polymorphisms with the risk of glioma: A hospital-based case-control study in a Chinese Han population.

Authors:  Shuo Zhang; Zhao Ye; Xiao Song; Gong Chen; Cong Huai; Qihan Wang; Jianping Song; Daru Lu; Yao Zhao; Hongyan Chen
Journal:  J Neurol Sci       Date:  2015-01-09       Impact factor: 3.181

Review 4.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

5.  Association between the G870A polymorphism of Cyclin D1 gene and glioma risk.

Authors:  Hailiang Zong; Lei Cao; Chong Ma; Jianping Zhao; Xing Ming; Ming Shang; Hongsheng Xu
Journal:  Tumour Biol       Date:  2014-05-20

6.  Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer.

Authors:  A M L Bedewy; M H Mostafa; A A Saad; S M El-Maghraby; M M L Bedewy; A M Hilal; L S Kandil
Journal:  J BUON       Date:  2013 Jan-Mar       Impact factor: 2.533

7.  Cyclin D1 G870A polymorphism and risk of colorectal cancer: a case control study.

Authors:  Aga Syed Sameer; Fazl Q Parray; Manzoor Ahmad Dar; Saniya Nissar; Mujeeb Zafar Banday; Sabha Rasool; G M Gulzar; Nissar A Chowdri; Mushtaq A Siddiqi
Journal:  Mol Med Rep       Date:  2013-01-24       Impact factor: 2.952

8.  The CCND1 G870A polymorphism and susceptibility to bladder cancer.

Authors:  Jing Li; Fei Luo; Hongtuan Zhang; Liang Li; Yong Xu
Journal:  Tumour Biol       Date:  2013-07-28

Review 9.  Epidemiology of primary brain tumors: current concepts and review of the literature.

Authors:  Margaret Wrensch; Yuriko Minn; Terri Chew; Melissa Bondy; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2002-10       Impact factor: 12.300

10.  EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment.

Authors:  Yuanjie Hu; Peter Dion Pioli; Eric Siegel; Qinghua Zhang; Jodi Nelson; Abhishek Chaturbedi; Marlon S Mathews; Daniel I Ro; Selma Alkafeef; Nelson Hsu; Mark Hamamura; Liping Yu; Kenneth R Hess; Bruce J Tromberg; Mark E Linskey; Yi-Hong Zhou
Journal:  Mol Cancer       Date:  2011-09-28       Impact factor: 27.401

View more
  4 in total

1.  CCDN1 rs603965 polymorphism may serve as a genetic biomarker of brain tumor: A meta-analysis of 5,769 subjects.

Authors:  Jiarong Lan; Min Li; Haifeng Wang
Journal:  Mol Genet Genomic Med       Date:  2019-04-10       Impact factor: 2.183

2.  The associations between common SNPs of EFEMP1 gene and glioma risk in Chinese population.

Authors:  Jun Hu; Dong Dong; Dandan Lu
Journal:  Onco Targets Ther       Date:  2017-11-06       Impact factor: 4.147

Review 3.  The Pathophysiological Significance of Fibulin-3.

Authors:  Imogen Livingstone; Vladimir N Uversky; Dominic Furniss; Akira Wiberg
Journal:  Biomolecules       Date:  2020-09-08

4.  Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities.

Authors:  Nicola J Armstrong; Karen A Mather; Muralidharan Sargurupremraj; Maria J Knol; Rainer Malik; Claudia L Satizabal; Lisa R Yanek; Wei Wen; Vilmundur G Gudnason; Nicole D Dueker; Lloyd T Elliott; Edith Hofer; Joshua Bis; Neda Jahanshad; Shuo Li; Mark A Logue; Michelle Luciano; Markus Scholz; Albert V Smith; Stella Trompet; Dina Vojinovic; Rui Xia; Fidel Alfaro-Almagro; David Ames; Najaf Amin; Philippe Amouyel; Alexa S Beiser; Henry Brodaty; Ian J Deary; Christine Fennema-Notestine; Piyush G Gampawar; Rebecca Gottesman; Ludovica Griffanti; Clifford R Jack; Mark Jenkinson; Jiyang Jiang; Brian G Kral; John B Kwok; Leonie Lampe; David C M Liewald; Pauline Maillard; Jonathan Marchini; Mark E Bastin; Bernard Mazoyer; Lukas Pirpamer; José Rafael Romero; Gennady V Roshchupkin; Peter R Schofield; Matthias L Schroeter; David J Stott; Anbupalam Thalamuthu; Julian Trollor; Christophe Tzourio; Jeroen van der Grond; Meike W Vernooij; Veronica A Witte; Margaret J Wright; Qiong Yang; Zoe Morris; Siggi Siggurdsson; Bruce Psaty; Arno Villringer; Helena Schmidt; Asta K Haberg; Cornelia M van Duijn; J Wouter Jukema; Martin Dichgans; Ralph L Sacco; Clinton B Wright; William S Kremen; Lewis C Becker; Paul M Thompson; Thomas H Mosley; Joanna M Wardlaw; M Arfan Ikram; Hieab H H Adams; Sudha Seshadri; Perminder S Sachdev; Stephen M Smith; Lenore Launer; William Longstreth; Charles DeCarli; Reinhold Schmidt; Myriam Fornage; Stephanie Debette; Paul A Nyquist
Journal:  Stroke       Date:  2020-06-10       Impact factor: 7.914

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.